- Home
- CLDX vs ECAT Comparison
CLDX vs ECAT Comparison
Compare CLDX & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- ECAT
- Stock Information
- Founded
- CLDX 1983
- ECAT 2021
- Country
- CLDX United States
- ECAT United States
- Employees
- CLDX N/A
- ECAT N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- CLDX Health Care
- ECAT Finance
- Exchange
- CLDX Nasdaq
- ECAT Nasdaq
- Market Cap
- CLDX 1.8B
- ECAT 1.8B
- IPO Year
- CLDX 2008
- ECAT N/A
- Fundamental
- Price
- CLDX $25.77
- ECAT $17.17
- Analyst Decision
- CLDX Buy
- ECAT
- Analyst Count
- CLDX 8
- ECAT 0
- Target Price
- CLDX $64.83
- ECAT N/A
- AVG Volume (30 Days)
- CLDX 992.8K
- ECAT 278.6K
- Earning Date
- CLDX 11-06-2024
- ECAT 01-01-0001
- Dividend Yield
- CLDX N/A
- ECAT 9.20%
- EPS Growth
- CLDX N/A
- ECAT N/A
- EPS
- CLDX N/A
- ECAT 2.39
- Revenue
- CLDX $9,976,000.00
- ECAT N/A
- Revenue This Year
- CLDX N/A
- ECAT N/A
- Revenue Next Year
- CLDX N/A
- ECAT N/A
- P/E Ratio
- CLDX N/A
- ECAT $7.15
- Revenue Growth
- CLDX 128.55
- ECAT N/A
- 52 Week Low
- CLDX $22.93
- ECAT $14.02
- 52 Week High
- CLDX $53.18
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- CLDX 45.64
- ECAT 43.42
- Support Level
- CLDX $24.48
- ECAT $17.05
- Resistance Level
- CLDX $26.66
- ECAT $17.71
- Average True Range (ATR)
- CLDX 1.19
- ECAT 0.19
- MACD
- CLDX 0.03
- ECAT -0.03
- Stochastic Oscillator
- CLDX 35.73
- ECAT 19.40
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.